Robert B Zaczek, Age 7460 Brush Mill Trl, Higganum, CT 06441
Robert Zaczek Phones & Addresses
60 Brush Mill Trl, Higganum, CT 06441
Pittsburgh, PA
331 Town Colony Dr, Middletown, CT 06457
18 Roosevelt Way, Avondale, PA 19311
Baltimore, MD
Haddam, CT
Wilmington, DE
Landenberg, PA
1316 Wightman St, Pittsburgh, PA 15217
Mentions for Robert B Zaczek
Publications & IP owners
Us Patents
Use Of Small Molecule Radioligands To Discover Inhibitors Of Amyloid-Beta Peptide Production And For Diagnostic Imaging
US Patent:
6737038, May 18, 2004
Filed:
May 17, 2000
Appl. No.:
09/573789
Inventors:
Robert Zaczek - Avondale PA
Richard E. Olson - Wilmington DE
Dietmar A. Seiffert - Boothwyn PA
Lorin A. Thompson - Wilmington DE
Richard E. Olson - Wilmington DE
Dietmar A. Seiffert - Boothwyn PA
Lorin A. Thompson - Wilmington DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 4900
US Classification:
424 92, 424 111, 424 165, 424 181, 424 91
Abstract:
This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimers disease, which involve elevated levels of A peptides.
Use Of Small Molecule Radioligands To Discover Inhibitors Of Amyloid-Beta Peptide Production And For Diagnostic Imaging
US Patent:
6878363, Apr 12, 2005
Filed:
May 17, 2001
Appl. No.:
09/859261
Inventors:
Robert Zaczek - Avondale PA, US
Richard E. Olson - Wilmington DE, US
Dietmar A. Seiffert - Boothwyn PA, US
Lorin A. Thompson - Wilmington DE, US
Richard E. Olson - Wilmington DE, US
Dietmar A. Seiffert - Boothwyn PA, US
Lorin A. Thompson - Wilmington DE, US
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K051/00
A61M036/14
A61M036/14
US Classification:
424 91, 424 111, 424 165, 424 181, 424 185, 435 23, 435 24
Abstract:
A method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.
Use Of Small Molecule Radioligands To Discover Inhibitors Of Amyloid-Beta Peptide Production And For Diagnostic Imaging
US Patent:
7153491, Dec 26, 2006
Filed:
Dec 11, 2003
Appl. No.:
10/734031
Inventors:
Robert Zaczek - Avondale PA, US
Richard E. Olson - Wilmington DE, US
Dietmar A. Seiffert - Boothwyn PA, US
Lorin Andrew Thompson - Wilmington DE, US
Richard E. Olson - Wilmington DE, US
Dietmar A. Seiffert - Boothwyn PA, US
Lorin Andrew Thompson - Wilmington DE, US
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
A61K 49/00
US Classification:
424 92, 424 111, 424 165, 424 91
Abstract:
This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.
Use Of Small Molecule Radioligands To Discover Inhibitors Of Amyloid-Beta Peptide Production And For Diagnostic Imaging
US Patent:
2005012, Jun 16, 2005
Filed:
Dec 21, 2004
Appl. No.:
11/018331
Inventors:
Robert Zaczek - Avondale PA, US
Richard Olson - Wilmington DE, US
Dietmar Seiffert - Boothwyn PA, US
Lorin Thompson - Wilmington DE, US
Richard Olson - Wilmington DE, US
Dietmar Seiffert - Boothwyn PA, US
Lorin Thompson - Wilmington DE, US
International Classification:
A61K051/00
US Classification:
424001110
Abstract:
This invention relates to a method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Furthermore, radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.
Use Of Small Molecule Radioligands To Discover Inhibitors Of Amyloid-Beta Peptide Production
US Patent:
6331408, Dec 18, 2001
Filed:
Nov 12, 1999
Appl. No.:
9/438901
Inventors:
Robert Zaczek - Avondale PA
Richard E. Olson - Wilmington DE
Dietmar A. Seiffert - Boothwyn PA
Lorin Andrew Thompson - Wilmington DE
Richard E. Olson - Wilmington DE
Dietmar A. Seiffert - Boothwyn PA
Lorin Andrew Thompson - Wilmington DE
International Classification:
C12Q 137
C12Q 100
G01N 3353
C12Q 100
G01N 3353
US Classification:
435 23
Abstract:
This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A. beta. peptides.
Composition For And Method Of Treating Neurological Disorders
US Patent:
6262081, Jul 17, 2001
Filed:
Jul 8, 1999
Appl. No.:
9/349906
Inventors:
Robert Zaczek - Avondale PA
Assignee:
DuPont Pharmaceuticals Company - Wilmington DE
International Classification:
A61K 31445
A61K 3144
A61K 3144
US Classification:
514332
Abstract:
The invention relates to a method of treating neurological disorders associated with neurotransmitter deficit in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one neurotransmitter release enhancer, and (ii) at least one acetylcholinesterase inhibitor. The invention also relates to compositions and kits containing the same.
Blockade Of Neuronal M-Channels As A Therapeutic Approach To The Treatment Of Neurological Disease
US Patent:
5750528, May 12, 1998
Filed:
Feb 1, 1995
Appl. No.:
8/384289
Inventors:
Barry Stephen Brown - Wilmington DE
Simon Piers Aiken - Greenville DE
Robert Zaczek - Avondale PA
Paul Richard Hartig - Princeton NJ
Christopher Allan Teleha - New Castle DE
Wendell Wilkie Wilkerson - New Castle DE
Richard Alan Earl - Wilmington DE
Simon Piers Aiken - Greenville DE
Robert Zaczek - Avondale PA
Paul Richard Hartig - Princeton NJ
Christopher Allan Teleha - New Castle DE
Wendell Wilkie Wilkerson - New Castle DE
Richard Alan Earl - Wilmington DE
Assignee:
The DuPont Merck Pharmaceutical Company - Wilmington DE
International Classification:
A61K 3150
A61K 31505
A61K 31445
A61K 3138
A61K 31505
A61K 31445
A61K 3138
US Classification:
514253
Abstract:
Compounds which block neuronal M-channels are useful for treating conditions involving neurotransmitter deficiencies, traumatic brain injury, or the depressive phase of bipolar disorder. Compounds can be evaluated for utility in treating these conditions by determining whether they are capable of blocking neuronal M-channels.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.